COMMUNIQUÉS West-GlobeNewswire

Park Dental Partners Rings the Closing Bell on the Nasdaq in New York
12/12/2025
MINNEAPOLIS, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (“Park Dental Partners” or the “Company”) , today announced that on December 11, 2025, members of the Park Dental Partners team rang the closing [...]
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
12/12/2025
Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s Exosomes TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone [...]
4DMT Announces New Employment Inducement Grants
12/12/2025
EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/12/2025
MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/12/2025
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
GRI Bio Announces Closing of $8.0 Million Public Offering
12/12/2025
LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the [...]
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
12/12/2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
Edesa Biotech Reports Fiscal Year 2025 Results
12/12/2025
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/12/2025
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Teva Releases Q4 2025 Aide Memoire
12/12/2025
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Q 4 2025 [...]
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12/12/2025
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday [...]
Extendicare Announces December 2025 Dividend of C$0.042 per Share
12/12/2025
MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
Genesis Healthcare Remains Committed to Securing Longterm Stability
13/12/2025
The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process centered around current and future patients, residents and staff KENNETT SQUARE, Pa., Dec. 12, 2025 ( [...]
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
12/12/2025
First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi ® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12, 2025 ( [...]
Anavar Steroid 2026: Legal Steroid Alternative, Anavar For Women Cycle, Dosage, Side Effects, Anavar Before And After Result (Anavar for Sale) Launch Alternative Anvarol By CrazyBulk
12/12/2025
Anavar Steroid: Cycle, Dosage, Side Effects, Most Popular Legal Steroids (Before And After Anavar Result) - Anavar for women (Anavar for Sale) - Buy Alternative Anvarol From CrazyBulk New York City,, Dec. 12, 2025 ( [...]
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
12/12/2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing [...]
DOC HOLLYWOOD: A Psychiatrist Takes 3rd Place with Baxter's Brain at the American Film Market Pitch Conference
12/12/2025
LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Dr. Walter Jacobson, a Los Angeles-based psychiatrist, author, and first-time filmmaker, scored a major win at this year’s American Film Market (AFM) Pitch Conference when [...]
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
12/12/2025
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA [...]
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
12/12/2025
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]

Pages